Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
4,434
Employees4,434
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
4,434
Employees4,434

NTRA Key Statistics

Market cap
31.16B
Market cap31.16B
Price-Earnings ratio
-95.59
Price-Earnings ratio-95.59
Dividend yield
Dividend yield
Average volume
1.70M
Average volume1.70M
High today
$229.95
High today$229.95
Low today
$211.98
Low today$211.98
Open price
$220.00
Open price$220.00
Volume
3.44M
Volume3.44M
52 Week high
$229.95
52 Week high$229.95
52 Week low
$125.38
52 Week low$125.38

Stock Snapshot

The current Natera(NTRA) stock price is $216.47, with a market capitalization of 31.16B. The stock trades at a price-to-earnings (P/E) ratio of -95.59.

On 2025-11-20, Natera(NTRA) stock traded between a low of $211.98 and a high of $229.95. Shares are currently priced at $216.47, which is +2.1% above the low and -5.9% below the high.

Natera(NTRA) shares are trading with a volume of 3.44M, against a daily average of 1.7M.

During the past year, Natera(NTRA) stock moved between $125.38 at its lowest and $229.95 at its peak.

During the past year, Natera(NTRA) stock moved between $125.38 at its lowest and $229.95 at its peak.

NTRA News

Simply Wall St 1d
How Investors May Respond To Natera Oncology Test Integration With Flatiron and Upbeat Guidance

Natera, Inc. reported robust third quarter results, raised its 2025 annual revenue and gross margin forecasts, and announced that Flatiron Health is integrating...

How Investors May Respond To Natera Oncology Test Integration With Flatiron and Upbeat Guidance
TipRanks 2d
Natera price target raised to $280 from $218 at UBS

UBS raised the firm’s price target on Natera (NTRA) to $280 from $218 and keeps a Buy rating on the shares. Meet Your ETF AI Analyst Discover how TipRanks' ET...

Analyst ratings

91%

of 22 ratings
Buy
90.9%
Hold
9.1%
Sell
0%

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.